Early diagnosis of impending femoral insufficiency fractures by use of MRI: case report and review of the literature

Cheon, Sang Ho; Oh, Chang Wug; Lee, Jung Yeop; Yi, Jae Hyuck; Cho, Hwan Seong; Oh, Jong Keon; Yang, Kyung‐Soo; Jung, Gu Hee

doi:10.1007/s00776-012-0218-8

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 11 ] Detection of subtle change at the STLC has been scrutinized whether it can be used as a predictor for AFF occurrence. [ 28 29 ] We believe that our study results suggest that not only image-based morphological changes, but also BMD measurement at the STLC is feasible and can be used as a monitoring tool for investigation related to the occurrence of AFF. On the basis, we should address that the BMD measurement at the medial and lateral cortices of the subtrochanteric femur were reproducible.…”

Section: Discussionmentioning

confidence: 82%

Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents

et al. 2016

View full text Add to dashboard Cite

BackgroundTo retrospectively assess whether the response of subtrochanteric lateral cortex (STLC) is different according to the bisphosphonate agents in terms of bone mineral density (BMD) change.MethodsA total of 149 subjects, who had 2- to 4-year interval follow-up of BMD using dual energy X-ray absorptiometry (DXA), were included in this retrospective study divided into following 3 groups: control group (no consumption of any anti-osteoporotic drugs, n=38), alendronate group (naïve alendronate users, n=48), risedronate group (naïve risedronate users, n=63). BMD was measured at the STLC and subtrochanteric medial cortex (STMC) in each patient by drawing rectangular ROIs at the bone cortices. The percent change of BMD at the STLC were compared between the aforementioned 3 groups by using analysis of covariance model to control five independent variables of age, body mass index, percent change of STMC, hip axis length, time interval between DXA examinations.ResultsThe least square mean values±standard deviation of the percent change of BMD in the control, alendronate, and risedronate groups were 1.46±1.50, 2.23±1.26, and 6.96±1.11, respectively. The risedronate group showed significantly higher change of BMD percentage compared with the control (adjusted P=0.012) or alendronate (adjusted P=0.016) groups.ConclusionsThe percent change of BMD at the STLC in the risedronate user group was greater than the alendronate and control groups. The implication of these changes needs to be further verified.

show abstract

Section: Discussionmentioning

confidence: 82%